JPRN-UMIN000053514尚未招募Unknown
Adjuvant therapy in pathological stage IA2-IIA EGFR-mutated NSCLC: a multicenter prospective observational study (WJOG17123L) - Adjuvant therapy in pathological stage IA2-IIA EGFR-mutated NSCLC: a multicenter prospective observational study (WJOG17123L)
适应症
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 入组人数
- 800
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients with active double cancers *1 2) Patients with a localized or systemically active infection requiring treatment 3) Pregnant women, lactating women, and women who may be currently pregnant 4) Patients with clinically problematic psychiatric disorders that would preclude enrollment in the study 5) Patients receiving continuous systemic administration of steroids or immunosuppressive agents 6) Patients with history of serious hypersensitivity 7) Exclusions for complications (i) History of ILD, drug-induced ILD, radiation pneumonitis requiring steroid therapy, or active ILD. (ii) Viral hepatitis HBs antigen positive or HCV antibody positive (iii) HIV-positive (but negative confirmation by serologic testing is not required). 8) Other cases deemed inappropriate by the physician in charge *1 Double cancers are defined as synchronous duplications and heterochronic duplications with a disease-free interval of 5 years or less. Carcinoma in situ (intraepithelial carcinoma) or intramucosal carcinoma equivalent lesions that are considered curable by local treatment are not included in active double cancers.
研究者
相似试验
进行中（未招募）
1 期
STUDY OF IMMUNE THERAPY (DURVALUMAB) BEFORE SURGERY IN EARLY STAGE NON SMALL CELL LUNG CANCERStage IB (> 4 cm), II Non Small Cell Lung Cancer resectableMedDRA version: 19.0Level: PTClassification code 10029517Term: Non-small cell lung cancer stage ISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10029518Term: Non-small cell lung cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-001849-15-FRIFCT
尚未招募
不适用
Phase II study of adjuvant therapy of alternate day oral therapy with S-1 for patients with curative resected biliary tract cancerbiliary tract cancerJPRN-UMIN000021459Gastrointestinal and pediatric surgery Tokyo medical university40
Unknown
2 期
Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel to Treat Lung CancerNon Small Cell Lung CancerNCT02191059Shandong Cancer Hospital and Institute60
已完成
3 期
IBCSG VI - Adjuvant therapy in node positive pre/perimenopausal breast cancer patients: CMF 3 vs. 6 with or without reintroduction of chemotherapy.Cancer - BreastBreast CancerACTRN12607000022460International Breast Cancer Study Group1,554
招募中
不适用
A Phase I/II Trial of combined adjuvant therapy with gemcitabine and cisplatin for resected biliary tract cancerResected biliary tract cancerJPRN-UMIN000004359Shinshu University School of Medicine, Surgery33